Chronic Pain and Opioid Use Disorder: Integrated Care

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Chronic pain and opioid use disorder (OUD) frequently require care from more than one clinical discipline. The central task is to assess the pain condition and the pattern of opioid use independently, then build a coordinated treatment plan that supports functioning, reduces overdose risk, and treats OUD when diagnostic criteria are met. Effective care can combine medications for OUD, diagnosis-specific pain treatments, physical rehabilitation, psychological therapies, and sustained follow-up. An OUD diagnosis does not invalidate a person's pain, and treatment for pain remains necessary during addiction recovery. The CDC Clinical Practice Guideline for Prescribing Opioids for Pain explicitly addresses coexisting pain and OUD.

The evidence is strongest for medication treatment of OUD with buprenorphine or methadone and for the principle that pain care should be individualized, multimodal, and reassessed over time. Evidence for specific combined pain-and-addiction service models is less mature: many trials exclude people with active OUD, and clinical outcomes depend on pain diagnoses, substance exposure, access to care, and social conditions. Integrated care therefore rests on established components delivered within a coherent clinical system, with uncertainties made explicit.

The Clinical Problem: Two Conditions That Influence One Another

Chronic pain is pain that persists or recurs for more than three months. Its consequences can include activity restriction, disrupted sleep, fatigue, depressed mood, social withdrawal, and difficulty maintaining work or family roles. Some chronic pain is clearly associated with a continuing tissue or neurological condition; other syndromes reflect complex changes in sensory processing and nervous-system responsiveness. Assessment seeks the most precise available pain diagnosis, including potentially treatable causes and warning signs of new disease.

OUD is a clinical disorder involving a problematic pattern of opioid use associated with meaningful impairment or distress. Opioids may have entered a person's life through a prescription for pain, through nonprescribed pharmaceutical opioids, or through an unregulated drug supply. A person can have disabling chronic pain without OUD, OUD without chronic pain, or both. The association between the two conditions is important because pain-related distress can affect substance use, while opioid exposure, withdrawal, sleep disruption, and other consequences of OUD can worsen pain experience and day-to-day function. ASAM's National Practice Guideline calls for pain treatment to be coordinated with OUD treatment.

A comprehensive plan consequently asks several simultaneous questions: What causes or maintains the pain? Does the person's opioid-use pattern meet OUD criteria? Which risks demand immediate attention? Which treatments are effective for the specific pain condition? Which medications best address OUD? How can the person continue meaningful activities and remain engaged in care? Answers change as symptoms, goals, and circumstances change.

Essential Definitions and Diagnostic Boundaries

Opioid exposure, physical dependence, and tolerance

Opioid exposure means taking or receiving an opioid, whether prescribed or otherwise. Physical dependence means the body has adapted so that reducing or stopping exposure can produce withdrawal symptoms. Tolerance describes a reduced response to an effect of the drug after repeated exposure. Both can occur during appropriate, closely supervised medical treatment and do not alone establish addiction. In DSM-5 diagnostic assessment, tolerance and withdrawal are not counted as OUD criteria when they arise solely from opioids taken under appropriate medical supervision.

The phrase "opioid dependence" has carried different clinical meanings across diagnostic systems and historical literature. For current American clinical communication, specifying physical dependence, OUD, or withdrawal avoids confusion. Withdrawal involves a distinct syndrome after reduction or cessation; intoxication is the acute effect of a substance; overdose is a potentially fatal toxic exposure, commonly characterized with opioids by dangerously suppressed breathing.

Risky use, misuse, and opioid use disorder

Risky opioid use increases the possibility of harm, for example through combinations with sedatives or inconsistent use of prescribed medications. "Misuse" describes use outside directions or intended purposes, but its meaning varies among studies and health systems. A single episode of nonadherence may warrant investigation without automatically proving OUD. Pain undertreatment, misunderstanding of instructions, cognitive impairment, changes in access to care, and emergent compulsive use each require different clinical responses.

OUD diagnosis examines the overall pattern: impaired control, craving, unsuccessful attempts to reduce use, much time spent obtaining or recovering from opioids, continuing use despite harm, failures in major obligations, and other DSM-5-TR criteria. Clinical severity is based on the number of applicable criteria, in context. Diagnosis is established through clinical evaluation rather than a pain score, urine result, prescription history, or screening questionnaire by itself. See the separate canonical clinical overview of Opioid Use Disorder: Symptoms, Risks, and Treatment.

Chronic pain and opioid-induced hyperalgesia

Hyperalgesia means an increased pain response to a painful stimulus. Opioid-induced hyperalgesia is a proposed and clinically described phenomenon in which prolonged opioid exposure may contribute to increased pain sensitivity in some circumstances. Distinguishing it from tolerance, withdrawal-associated pain, disease progression, new injury, and changes in psychological stress is difficult. Evidence from experimental systems and some clinical settings supports biological plausibility, but clinicians should not use the term as an automatic explanation for every case of worsening pain during long-term opioid treatment. Decisions about opioid changes require individualized evaluation.

Why Pain and Opioid Use Disorder Can Reinforce Each Other

Nociception, sensitization, and function

Pain emerges through interactions among peripheral tissue signals, spinal pathways, brain networks involved in sensation and salience, expectations, memories, and social context. Neuropathic, inflammatory, nociplastic, and mixed pain mechanisms can overlap in one patient. Persistent pain often changes movement patterns, sleep, mood, attention, and confidence. Reduced activity can contribute to physical deconditioning, while fear of movement may increase disability even when safe graded activity would be beneficial.

Reward, reinforcement, relief, and craving

Opioid medications can initially reduce nociceptive pain and also produce relief from distress or withdrawal. Relief can reinforce repeated use. Over time, conditioning, environmental cues, changes in motivational salience, and increasingly negative consequences may sustain compulsive use in OUD. Pain flares can become learned triggers for craving; withdrawal itself can create body pain, autonomic symptoms, and anxiety. A complete clinical formulation distinguishes pain relief, anticipated relief, withdrawal avoidance, and compulsive use instead of attributing every request for analgesia to addiction.

Sleep, mood, trauma, and social stressors

Insomnia, depression, anxiety, trauma histories, social isolation, housing instability, and job insecurity can alter pain interference and make sustained OUD treatment harder. Their causal roles differ by patient and cannot be assumed from coexistence. Clinicians should screen for depression and suicide risk when indicated, ask about trauma with sensitivity, evaluate sleep problems, and identify practical barriers to appointments, medications, exercise, transportation, and recovery support. People frequently need accessible and reliable treatment systems as much as they need a new clinical intervention.

Clinical Assessment: A Structured but Individualized Approach

Establish a specific pain diagnosis

A pain assessment covers onset, location, duration, character, radiation, neurological features, previous injuries and illnesses, prior treatment response, functional limitations, work and family demands, sleep, and what the patient hopes to regain. Examination and imaging are selected according to the suspected condition and clinical warning signs. Escalating weakness, new bowel or bladder dysfunction with relevant neurological symptoms, fever with serious back pain, or new severe pain with systemic illness warrants prompt assessment for dangerous underlying conditions. The label "chronic pain" should never conceal an evolving medical disorder.

Assess the opioid-use pattern and diagnose OUD when indicated

The clinician obtains a nonjudgmental account of prescribed and nonprescribed opioids, frequency and route of exposure, changes over time, cravings, control over use, social and medical consequences, prior overdose, and withdrawal experiences. Prescription monitoring information and toxicology can help identify risks or unexpected exposures; results require interpretation, awareness of assay limitations, and transparent discussion. Neither test establishes compulsive behavior by itself. A validated screening tool identifies who warrants fuller assessment; diagnostic interviews apply clinical criteria. The CDC guideline directs clinicians to assess suspected OUD with DSM criteria and offer effective treatment when diagnosed.

Measure multiple outcomes at baseline

Useful assessments include average and worst pain intensity, pain interference, mobility, sleep, meaningful activities, emotional symptoms, opioid cravings, nonprescribed substance use, medication adherence, side effects, and overdose history. Pain scales capture one dimension of illness; a patient may improve greatly in daily activities without becoming pain-free. The Brief Pain Inventory and validated measures of physical function can aid measurement over time, while instruments for anxiety, depression, and substance use can guide indicated follow-up. Goals should be framed in concrete patient-valued terms and revisited rather than treated as fixed targets.

Evaluate medication combinations and medical vulnerabilities

Review all prescriptions, over-the-counter products, alcohol, sedative medications, and other substances. Combining opioids with benzodiazepines, alcohol, or other central nervous system depressants increases respiratory risk. Assess sleep apnea and other respiratory illness, liver and kidney conditions, cardiac disease, fall risk, cognition, pregnancy potential and pregnancy status, and prior medication complications. Risk assessment should support a safer plan and should not become a reason to deny OUD treatment or abandon pain care.

Immediate Safety: Emergencies and High-Risk Transitions

Slow, shallow, or absent breathing; unresponsiveness; blue or gray lips; and suspected opioid overdose require immediate emergency services. Administer naloxone if available, follow emergency-dispatch instructions, and remain with the person while help is on the way. Naloxone reverses opioid effects temporarily, and additional emergency treatment may be necessary. Clinicians should offer overdose education and access to naloxone to patients at elevated risk and to people likely to witness an overdose. See CDC guidance on naloxone.

Acute severe sedation, confusion, respiratory symptoms, or suspected co-ingestion of sedatives warrants urgent assessment even if an individual normally takes prescribed opioids. Abrupt interruption of long-term opioid treatment can precipitate withdrawal and serious destabilization; CDC recommends against sudden discontinuation or rapid dose reductions except when a life-threatening event requires emergency intervention. Suicidal thoughts with intent or inability to stay safe require immediate clinical or emergency evaluation. These situations are managed as medical and psychiatric safety problems, not as disciplinary violations.

Evidence-Based Treatment of Opioid Use Disorder

Buprenorphine: a cornerstone that can coexist with pain treatment

Buprenorphine is a partial mu-opioid receptor agonist with established efficacy for OUD. It suppresses withdrawal and craving, supports treatment retention, and is associated with reduced exposure to unregulated opioids. Its ceiling on respiratory depression relative to full agonists can improve the safety profile, although overdose remains possible, particularly with other sedating substances. For people with chronic pain, buprenorphine may also contribute to analgesia, but an OUD treatment plan should not be judged solely by pain reduction. Cochrane's review of buprenorphine maintenance and CDC treatment guidance support its role in ongoing OUD care.

OUD formulations, pain-indicated formulations, prescribing indications, and clinical schedules are not interchangeable. Analgesic effects may last for a shorter interval than OUD symptom control, so clinicians sometimes coordinate administration timing in patients with both conditions. Initiation and medication transitions require assessment of existing opioid exposure and the possibility of precipitated withdrawal; these decisions belong within a supervised, individualized treatment plan. The separate medication article, where published, owns detailed medication selection and initiation protocols.

Methadone: effective OUD treatment requiring careful coordination

Methadone is a full opioid agonist with strong evidence for OUD treatment retention and reduction of illicit opioid use. Maintenance treatment is associated with substantially lower mortality during treatment than periods outside treatment in observational cohorts. Methadone can have analgesic effects, but its accumulation, drug interactions, QT-related cardiac concerns in selected patients, and respiratory effects require careful monitoring. In the United States, methadone for OUD is generally provided through certified opioid treatment programs. A pain clinician and the OUD treatment program should share relevant information with the patient's consent and coordinate any additional analgesic care. Sordo and colleagues' systematic review documents mortality differences across treatment periods; it cannot by itself eliminate confounding inherent to cohort research.

Extended-release naltrexone: different trade-offs

Naltrexone is an opioid receptor antagonist used for appropriately selected patients with OUD. Starting it requires a clinician-verified opioid-free state to avoid precipitated withdrawal, and ongoing blockade complicates emergency or planned opioid analgesia. People experiencing significant chronic pain that may require opioid therapy need especially careful evaluation of treatment preferences, access to nonopioid therapies, and how future acute pain would be managed. Randomized OUD research supports naltrexone in selected groups, but initiation barriers, adherence, and comparative retention limit generalization. For many patients with active pain and continuing opioid exposure, buprenorphine or methadone can be clinically more practical.

Why withdrawal management alone is insufficient

Short-term management of opioid withdrawal can stabilize immediate symptoms and prepare a person to enter treatment, yet it does not provide sustained protection against OUD recurrence. Reduced opioid tolerance after abstinence increases overdose risk if a person later returns to use. CDC's 2024 clinical guidance explicitly recommends medication treatment and warns against detoxification alone. Duration of effective OUD treatment is individualized; an arbitrary medication end date may be harmful.

Managing Chronic Pain Alongside OUD Medication

Pain-specific therapies should lead the analgesic plan

The first question is which treatment targets the patient's pain mechanism and functional limitations. Depending on diagnosis, options may include supervised therapeutic exercise, physical therapy, pacing and graded reactivation, sleep interventions, cognitive behavioral approaches, topical therapies, nonsteroidal anti-inflammatory drugs when appropriate, selected antidepressants with analgesic effects, neuropathic pain medications for indicated conditions, or procedural interventions where evidence and individual anatomy support them. Medication selection must account for kidney, liver, gastrointestinal, cardiovascular, pregnancy-related, and other risks. For chronic low back pain, the American College of Physicians guideline endorses appropriate nonpharmacologic interventions as initial options.

Evidence varies by diagnosis and treatment. Rehabilitation for chronic musculoskeletal pain cannot simply be transferred without adjustment to neuropathic pain, inflammatory disease, complex regional pain syndromes, sickle cell disease, cancer pain, or palliative settings. Management of these specific conditions belongs to relevant clinical specialists and disease-specific guidance; the present article concerns the integrated clinical process when OUD and persistent pain coexist.

Nonopioid analgesics and medication reconciliation

Nonopioid drugs may provide meaningful benefit for selected pain mechanisms. Topical anti-inflammatory drugs can limit systemic exposure in some localized conditions; oral NSAIDs may benefit inflammatory or musculoskeletal pain but can cause gastrointestinal bleeding, renal injury, and cardiovascular harms. Duloxetine and selected anticonvulsant drugs are used for particular neuropathic or other chronic pain indications, with variable effectiveness and tolerability. Sedating co-medications require extra caution when combined with methadone, buprenorphine, or other opioids. A complete medication review prevents duplicated therapy and identifies drugs being used without clear ongoing benefit.

What randomized evidence says about long-term opioid analgesia

In the 12-month SPACE pragmatic randomized trial, 240 primary care patients with chronic back or hip/knee osteoarthritis pain were assigned opioid or nonopioid medication strategies. Opioids did not produce better pain-related function, and the opioid arm reported more medication-related adverse symptoms. The study does not show that every opioid is ineffective for every pain condition, and it excluded people with physiological dependence on ongoing opioids; results therefore cannot be extrapolated directly to patients in OUD treatment. Its central contribution is to challenge routine initiation of long-term full-agonist opioids for common chronic musculoskeletal pain when nonopioid care is feasible. Krebs and colleagues, JAMA, 2018.

Behavioral treatment for pain and emotional distress

Pain-focused cognitive behavioral therapy helps patients identify unhelpful avoidance cycles, adapt activity and sleep habits, regulate stress, and build manageable functional goals. Acceptance and commitment therapy emphasizes psychological flexibility and action consistent with personal values while symptoms are present. These interventions are compatible with medications for OUD and may address pain interference and distress. A 2020 Cochrane review involving 75 trials and 9,401 participants found mostly small or very small average effects of CBT on pain, disability, and distress; the studies generally did not establish comparable effectiveness specifically in people with active OUD.

An overview of ACT systematic reviews suggests possible benefits for psychological factors and selected functional outcomes, but overlapping evidence, variable review quality, and diverse patient populations limit strong generalization. Psychological therapies are clinical treatments and skills-building approaches; their usefulness does not imply that the pain is imaginary or entirely psychological.

Coordinating Buprenorphine, Methadone, and Acute Pain Needs

Continuity during pain flares

A patient taking buprenorphine or methadone for OUD can develop a new injury, painful dental condition, postoperative pain, or exacerbation of an existing disorder. Clinicians should reassess the acute cause and use appropriate multimodal analgesia. OUD medication should be treated as a continuing core treatment rather than automatically interrupted because additional pain care is needed. Depending on circumstances, an experienced care team may adjust medication timing, use local or regional anesthesia, or add other supervised analgesic options while monitoring sedation and respiratory risk. The ASAM guideline supports coordinated pain management for people with OUD.

Surgery and other planned procedures

Before a procedure, clinicians should communicate with the patient, the OUD prescriber, the surgeon, anesthesia and acute pain teams, and relevant caregivers with permission. A plan should identify expected pain severity, current OUD treatment, existing tolerance and other medications, regional anesthesia options, postoperative monitoring, relapse and overdose risks, and a reliable handoff back to outpatient care. A multisociety expert panel recommends that buprenorphine generally should not be routinely discontinued perioperatively, emphasizing individualized pain treatment and avoidance of OUD recurrence. This guidance is based substantially on expert consensus and heterogeneous clinical evidence, not a universal randomized protocol.

Methadone maintenance and additional analgesia

Methadone maintenance used for OUD may suppress withdrawal for a long interval while its analgesic duration is shorter. Acute pain therefore may require separate assessment and treatment rather than assuming an OUD maintenance regimen addresses all pain. Because of pharmacokinetic variability and interaction risks, any changes must be coordinated with the opioid treatment program and specialists familiar with the patient's clinical state. Prescribing decisions are more complex during hospital admissions and transitions between care settings.

When Long-Term Prescribed Opioids Have Become Risky

A careful review before changing treatment

Patients receiving long-term full-agonist analgesics may face inadequate functional benefit, excessive sedation, repeated overdose, unsafe medication combinations, or evidence of OUD. Clinicians should revisit the original pain diagnosis, screen for evolving OUD, review possible nonopioid therapies, and explore the person's goals and concerns. An unanticipated problem with opioid dosing requires assessment rather than immediate dismissal from care. Documentation should distinguish objectively observed safety findings from interpretations about intent or motivation.

Patient-centered tapering and its hazards

When the risks of continued opioid analgesia outweigh benefits, a collaborative, individually paced reduction may be appropriate, with adequate support, monitoring, and continued pain treatment. Abrupt discontinuation or rapid forced tapering can precipitate withdrawal and destabilization. A large retrospective cohort analysis found that periods after dose tapering were associated with higher rates of overdose or withdrawal and mental health crisis; observational design means this does not establish that tapering caused all of those events. Fenton and colleagues' study reinforces the need for individualized decisions, transparent consent, and follow-up. The CDC guideline explicitly cautions against abrupt discontinuation for stable patients outside urgent life-threatening situations.

Rotation to buprenorphine: a promising option with evidence limits

Some patients receiving long-term opioids for pain, including those whose prescribing regimens carry substantial risk, may be considered for transition to buprenorphine after expert assessment. In a systematic review of 22 studies including 1,616 participants, buprenorphine rotation was associated with maintained or improved pain in the available studies, but most evidence was low or very low certainty and many designs were vulnerable to bias. This evidence concerns a heterogeneous population on long-term opioid therapy and should not be mistaken for a definitive randomized comparison of integrated care programs among people with confirmed OUD. Powell and colleagues, 2021.

Treatment transitions require attention to precipitated withdrawal, concurrent medications, diagnosis, and patient-specific monitoring. Choice of formulation, initiation method, and clinical setting belongs to qualified clinicians. A 2024 Veterans Affairs guidance document distinguishes buprenorphine used for chronic pain from its established life-preserving role in OUD and recommends interdisciplinary support during high-risk transitions.

What Integrated Care Looks Like in Practice

One shared plan with distinct clinical responsibilities

An integrated service identifies a responsible clinical lead and makes communication predictable among primary care, addiction medicine, pain specialists, behavioral health, rehabilitation, pharmacy, and relevant social services. The care plan specifies which professional assesses each new symptom, who prescribes OUD medication, who manages other analgesics, how emergencies are handled, and how information is exchanged with the patient's consent. A patient should not have to choose between treating pain and continuing OUD medication.

At the initial visit, clinicians establish a pain diagnosis, confirm or exclude OUD, review overdose risk, and create an immediate safety and continuity plan. Over subsequent encounters, treatment aims may include reduced opioid cravings and unregulated opioid exposure, increased capacity for work or self-care, better sleep, tolerable pain interference, and improved social participation. When services are fragmented, arranging warm handoffs and predictable follow-up is a clinical intervention in its own right, although comparative trial evidence on the ideal organizational model is limited.

Shared decision-making and nonstigmatizing communication

A workable plan takes seriously a patient's prior experiences of pain relief, withdrawal, stigma, treatment failure, and medical mistrust. Clinicians explain why a proposed treatment could help, what the evidence supports, what side effects matter, and what alternatives exist. They ask permission before contacting outside providers and make space for disagreement over goals. Monitoring is explained as a shared safety tool; unexpected results trigger conversation and reassessment. Respectful care increases the possibility that a patient will disclose changing symptoms or substance exposure before a preventable crisis.

Functional goals and measurement-based follow-up

Outcome review should include pain interference, movement tolerance, sleep, mood, ability to maintain daily routines, side effects, cravings, use of nonprescribed opioids, overdose events, retention in OUD treatment, and patient-reported quality of life. One person's early success may be consistent attendance and fewer overdoses; another's may be returning to exercise or caregiving. Pain intensity alone misses important gains. Treatment changes follow the combined evidence from clinical response, risk profile, and patient priorities.

Harm reduction within ongoing care

Education about overdose, access to naloxone, awareness of the risks from alcohol and sedative co-use, and safer continuity of OUD medication are relevant throughout treatment. In settings where drug checking and syringe services are available, they can reduce particular harms and support connection to care. Harm reduction approaches do not require a patient to reach a specified stage of recovery before gaining protection. Counseling should emphasize the unpredictability of unregulated opioid supply and the need for emergency assistance when overdose is suspected.

Special Populations and Contexts

Pregnancy and the postpartum period

Pregnancy adds fetal and maternal safety considerations, changing physiology, and urgency around stable engagement with care. For pregnant patients with OUD, buprenorphine or methadone is generally recommended over withdrawal management alone. Pain diagnoses, medications, obstetric status, and neonatal planning require coordinated obstetric, addiction, and pain services. Abrupt treatment changes can create significant maternal and fetal risk. The CDC prescribing guideline addresses treatment of OUD during pregnancy and the need for specialist coordination.

Adolescents and younger adults

In adolescents and young adults, clinicians assess development, school and family context, medication access, pain conditions, safeguarding needs, and confidentiality laws. Screening and treatment should be age-appropriate, with family participation when clinically beneficial and legally suitable. Evidence for many chronic pain and OUD interventions derives mainly from adult populations, so estimates of effect should not be applied uncritically to minors. Youth with persistent pain and opioid exposure deserve prompt, coordinated evaluation rather than adult-centered protocols by default.

Older adults and medically complex patients

Older adults may face multimorbidity, cognitive changes, falls, drug interactions, impaired renal function, and fragmented prescribing. A pain plan should consider function, frailty, home support, and whether the person can safely manage medication schedules. OUD can be overlooked when symptoms are attributed to aging or long-standing illness. Clinical review should consider delirium, medication toxicity, and other acute causes whenever mental status or mobility changes unexpectedly.

Trauma, serious mental illness, and unstable housing

For people with trauma histories or severe mental illness, care may need adapted communication, crisis plans, and integrated psychiatric support. Housing insecurity complicates secure storage of medications, sleep, rehabilitation, and appointment attendance. These needs are addressed through targeted services and accommodations. Trauma and OUD comorbidity has its own diagnostic and treatment questions, distinct from the focused problem of integrating persistent pain treatment with OUD care.

Understanding the Evidence: Strong Foundations and Remaining Questions

Established evidence supports medication treatment for OUD, with particularly strong support for buprenorphine and methadone. Large observational syntheses link time in opioid agonist treatment with lower mortality, though observational comparisons can retain residual confounding. Chronic pain guidelines support condition-specific nonpharmacologic and nonopioid treatments, and randomized trials show modest benefits from selected psychological therapies. For common chronic musculoskeletal pain, randomized evidence does not establish superior long-term function with opioid strategies compared with nonopioid strategies.

More limited evidence addresses how these components perform when combined for patients who simultaneously have active OUD and disabling chronic pain. Studies often vary in how OUD is defined, whether patients are receiving methadone or buprenorphine, which pain diagnoses are included, how outcomes are measured, and how long participants remain in treatment. The evidence for buprenorphine rotation in long-term opioid analgesic recipients is promising but largely low certainty. Surgical buprenorphine recommendations reflect clinical consensus as well as observational evidence. A claim that one universally optimal combined regimen exists would exceed the available data.

Clinical research also must distinguish associations from causal effects. People retained in OUD treatment may differ systematically from those who leave. Patients selected for tapering often have prior safety concerns and complicated conditions. Trials conducted in veteran clinics or specialty programs may not represent pregnant patients, adolescents, people experiencing homelessness, or people with complex psychiatric and medical conditions. These limitations support cautious interpretation of effect sizes and stronger real-world follow-up rather than therapeutic inaction.

A Practical Clinical Decision Framework

The first decision is whether an emergency is present: suspected overdose, respiratory compromise, major neurological change, severe acute medical illness, or immediate suicide danger demands urgent care. Once the person is stable, clinicians determine the pain mechanism and functional impact while independently examining OUD criteria, opioid exposure, withdrawal risk, and co-occurring conditions. A confirmed OUD diagnosis triggers an offer of evidence-based medication treatment; chronic pain triggers appropriate condition-specific analgesia, rehabilitation, and ongoing assessment.

Next, the team integrates the medication plan. It avoids unplanned interruptions of OUD treatment, reviews sedative combinations, clarifies who manages acute pain, and prepares for future procedures and hospitalizations. It offers naloxone when indicated and agrees on measurable goals. Reassessment addresses both illnesses together: changing pain does not automatically imply addiction recurrence, and changing substance use does not erase legitimate pain. The best outcome is a durable, patient-centered therapeutic relationship capable of adjusting as clinical needs evolve.

Frequently Asked Questions

Can prescribed opioid treatment cause physical dependence without opioid use disorder?

Yes. Physical dependence and tolerance can develop during appropriate medical treatment. OUD requires a clinically significant pattern of impaired control and related harm or distress established through diagnostic assessment. Tolerance and withdrawal that occur solely during appropriate medical supervision are not counted toward DSM-5 OUD diagnosis. Patients who develop withdrawal symptoms after a prescribed dose change still deserve medical care and appropriate pain management.

Does an OUD diagnosis mean clinicians should stop treating chronic pain?

No. Persistent pain requires assessment and treatment whether or not OUD is present. An OUD diagnosis changes the risk-benefit analysis of medications and calls for coordinated OUD treatment, but it does not invalidate pain symptoms or justify dismissing the patient. The central aim is to improve safety, functioning, and quality of life through individualized care.

Is buprenorphine a pain treatment, an addiction treatment, or both?

Buprenorphine has clinically relevant roles in both areas, but indications and formulations differ. Its evidence base for OUD is strong; evidence supporting particular buprenorphine strategies for chronic pain in complex populations is more variable. The OUD prescriber and pain clinicians decide how to coordinate therapy without conflating the goals or interrupting life-preserving treatment.

Is methadone maintenance enough to treat every kind of pain?

No. Methadone maintenance treats OUD and may provide some analgesia, yet acute or chronic pain may require separate diagnosis-specific treatment. Analgesic duration, adverse effects, and drug interactions call for coordination with the opioid treatment program rather than unsupervised medication changes.

Should buprenorphine always be stopped before surgery?

Current multisociety consensus recommends against routinely discontinuing buprenorphine before surgery. Care teams plan analgesia individually with anesthesia, surgery, addiction, and pain clinicians, taking account of expected procedure-related pain and risks to OUD stability. The decision cannot be reduced to one rule applied without clinical context.

Does tapering prescribed opioids automatically improve safety?

No. Any change should depend on the person's circumstances, benefits, risks, and goals. Abrupt or forced rapid changes can lead to withdrawal, distress, care disruption, and overdose risks. Observational studies of tapering underscore the importance of careful monitoring and support. When OUD is diagnosed, medication treatment for OUD should be offered.

Can psychological therapy reduce pain if someone has OUD?

Psychological therapies can help patients respond to pain, regain activity, and manage distress, and they may complement OUD care. Average benefits for chronic pain in large reviews are often modest, and studies focused specifically on active co-occurring OUD are fewer. Such care is one component of a medically integrated plan.

What outcomes indicate successful integrated care?

Meaningful outcomes include fewer overdoses, sustained engagement in OUD treatment, reduced harmful opioid exposure, improved daily function, sleep, mobility, participation, and greater patient-reported quality of life. Change may occur at different rates across domains. Successful care is individualized and measured over time rather than defined by one pain number or a single recovery pathway.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the parent scientific chapter and its verified English research catalog.

Opioid Use Disorder: Symptoms, Risks, and Treatment — diagnosis, clinical risks, treatment principles, and recovery.

Opioid Withdrawal: Symptoms, Timeline, and Treatment — withdrawal presentation and supervised management.

Substance Use Disorder: Symptoms, Diagnosis, and Treatment — wider clinical foundations across substances.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — differential assessment of symptoms and substance-related anxiety.

References

American College of Physicians. Qaseem A, Wilt TJ, McLean RM, Forciea MA. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline. Annals of Internal Medicine. https://doi.org/10.7326/M16-2367

American Society of Addiction Medicine. (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Journal of Addiction Medicine. https://doi.org/10.1097/ADM.0000000000000633

Centers for Disease Control and Prevention. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. Morbidity and Mortality Weekly Report. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm

Centers for Disease Control and Prevention. (2024). About Naloxone. https://www.cdc.gov/overdose-prevention/reversing-overdose/about-naloxone.html

Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html

Fenton JJ, Magnan E, Tseregounis IE, et al. (2022). Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2022.16726

Kohan L, Potru S, Barreveld AM, et al. (2021). Buprenorphine management in the perioperative period: Educational review and recommendations from a multisociety expert panel. Regional Anesthesia and Pain Medicine. https://doi.org/10.1136/rapm-2021-103007

Krebs EE, Gravely A, Nugent S, et al. (2018). Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2018.0899

Martinez-Calderon J, García-Muñoz C, Rufo-Barbero C, et al. (2024). Acceptance and commitment therapy for chronic pain: An overview of systematic reviews with meta-analysis of randomized clinical trials. Journal of Pain. https://doi.org/10.1016/j.jpain.2023.09.013

Mattick RP, Breen C, Kimber J, Davoli M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD002207.pub4

Powell VD, Rosenberg JM, Yaganti A, et al. (2021). Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: A systematic review. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.24152

Sordo L, Barrio G, Bravo MJ, et al. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. https://www.bmj.com/content/357/bmj.j1550

Veterans Health Administration. (2024). Buprenorphine for the management of chronic pain: National guidance document. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Buprenorphine_for_Chronic_Pain_RFU_AUG_2024_Update.pdf

Williams AC de C, Fisher E, Hearn L, Eccleston C. (2020). Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD007407.pub4